The Schall Law Firm Begins A Probe Into Allegations Against Zoetis Inc And Urges Investors With Losses To Reach Out
LOS ANGELES, CA / ACCESSWIRE / July 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investigation Into Claims Against Zoetis Inc Is Initiated By The Schall Law Firm And Investors Who Have Suffered Losses Are Encouraged To Contact
LOS ANGELES, CA / ACCESSWIRE / July 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Begins Investigation Into Allegations Against Zoetis Inc And Encourages Investors With Losses To Reach Out
LOS ANGELES, CA / ACCESSWIRE / July 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Zoetis Deep Dive: Better Setup Than Human Pharma
Zoetis is a leading animal pharmaceutical developer with 92% of sales from animal pharmaceuticals, over two-thirds of which are for pets. The company's competitive advantage lies in its R&D success, lower spending on R&D compared to human pharma, and a distribution network of unrivaled scale. Zoetis' growth is driven by pet humanization trends, but future success hinges on innovation and new drug releases, particularly the upcoming drug Librela.
The Schall Law Firm Commences Inquiry Into Claims Against Zoetis Inc And Invites Investors With Losses To Communicate
LOS ANGELES, CA / ACCESSWIRE / July 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Initiates Examination Of Accusations Against Zoetis Inc And Urges Investors With Losses To Get In Touch
LOS ANGELES, CA / ACCESSWIRE / July 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Starts Probe Into Allegations Against Zoetis Inc And Encourages Investors With Losses To Contact
LOS ANGELES, CA / ACCESSWIRE / July 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Zoetis: Still A High Quality Business Led By Companion Animal Growth
Zoetis's stock has slumped in 2024, partly due to recent safety concerns regarding the company's arthritis drugs. Despite these safety concerns, Zoetis grew total revenue by 10% compared to Q1 2023 and raised their full-year 2024 revenue guidance. The company's companion animal products are supporting Zoetis's growth as the company sees a large opportunity with their osteoarthritis pain drugs.
Investors With Losses Are Invited By The Schall Law Firm To Reach Out As They Start Investigation Into Claims Against Zoetis Inc
LOS ANGELES, CA / ACCESSWIRE / July 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Zoetis: A High-Quality Business And Fast Dividend Growth At A Reasonable Price
Zoetis is a resilient company that shows strong growth even in times of economic challenges. The company is well-positioned in a growing market and has a strong product portfolio, including a new potential billion-franchise in osteoarthritis pain. ZTS has shown impressive dividend growth in recent years, and it is likely this will continue in the future, making it attractive for dividend investors with a long time horizon.
The Schall Law Firm Begins Investigation Into Claims Against Zoetis Inc And Invites Investors With Losses To Reach Out
LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Starts Probe Into Accusations Against Zoetis Inc And Encourages Investors With Losses To Contact
LOS ANGELES, CA / ACCESSWIRE / July 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
